Intellia

In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.

UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.

The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.

The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

The gene editing firm will concurrently offer 5 million shares to the public and $55 million worth of shares at the same price in a private placement.

The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.